Valuation: Cytokinetics, Inc.

Market Cap 1.1TCr 962.8Cr 895.39Cr 821.63Cr 1.54TCr 1,05600Cr 1.57TCr 11TCr 4.15TCr 52TCr 4.12TCr 4.03TCr 1,79400Cr P/E 2026 *
-12.6x
P/E 2027 * -17.3x
Enterprise Value 1.04TCr 911.31Cr 847.5Cr 777.69Cr 1.46TCr 1LCr 1.48TCr 10TCr 3.93TCr 49TCr 3.9TCr 3.81TCr 1,69800Cr EV / Sales 2026 *
91.9x
EV / Sales 2027 * 26.3x
Free-Float
98.24%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2007
Director of Finance/CFO 55 08/05/2024
Chief Administrative Officer 57 14/11/2025
Director TitleAgeSince
Director/Board Member 62 01/01/2007
Chairman 81 08/04/2022
Director/Board Member 78 09/02/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%+6.97%+62.83%+67.97% 5.73TCr
-1.92%+6.03%+43.68%+84.56% 5.5TCr
-0.46%-1.29%+3.28%+422.58% 2.32TCr
-2.97%-2.35%-22.03%-16.54% 2.26TCr
-0.36%+5.73%+30.99%-3.58% 2.05TCr
-1.34%+0.51%+25.02%-30.27% 1.76TCr
-1.44%+5.67%+32.54%+544.11% 1.57TCr
-1.30%-5.02%+165.62%+291.37% 1.45TCr
-0.50%-0.98%+23.62%+178.38% 1.39TCr
Average -1.04%+1.28%+40.62%+170.95% 2.67TCr
Weighted average by Cap. -0.87%+2.10%+41.18%+135.69%

Financials

2026 *2027 *
Net sales 11Cr 9.91Cr 9.22Cr 8.46Cr 16Cr 1.09TCr 16Cr 109.48Cr 43Cr 534.38Cr 42Cr 41Cr 1.85TCr 39Cr 35Cr 32Cr 29Cr 55Cr 3.79TCr 56Cr 381.55Cr 149.07Cr 1.86TCr 147.68Cr 144.49Cr 6.44TCr
Net income -80Cr -70Cr -65Cr -60Cr -112.29Cr -7.68TCr -114.03Cr -773.4Cr -302.16Cr -3.78TCr -299.34Cr -292.89Cr -13TCr -65Cr -57Cr -53Cr -49Cr -92Cr -6.3TCr -94Cr -634.86Cr -248.03Cr -3.1TCr -245.72Cr -240.42Cr -11TCr
Net Debt -59Cr -51Cr -48Cr -44Cr -83Cr -5.65TCr -84Cr -568.69Cr -222.18Cr -2.78TCr -220.1Cr -215.36Cr -9.6TCr -61Cr -53Cr -49Cr -45Cr -85Cr -5.83TCr -87Cr -587.47Cr -229.52Cr -2.87TCr -227.38Cr -222.47Cr -9.91TCr
Logo Cytokinetics, Inc.
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-